Contemporary Characteristics of Penile Cancer
September 18, 2025 updated by: M.D. Anderson Cancer Center
Contemporary Characteristics of Penile Carcinoma: at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, the Woodlands and Bay Area Regional Care Centers
This study develops a prospective database of patients who are evaluated and treated for penile cancer.
This will facilitate analyzing trends in cancer incidence, risk factors, treatment, complications, and tumor progression.
It will also prospectively validate the importance of pathological prognostic factors previously reported and outcome related to contemporary treatment.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To prospectively collect data on the presenting features, management and outcome of penile carcinoma at M.D. Anderson Cancer Center, and Harris Health System and Katy, Sugar Land, The Woodlands and Bay Area Regional Care Centers.
OUTLINE:
Patients undergo data collection every 6 months for up to 15 years.
Study Type
Observational
Enrollment (Actual)
499
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with a primary penile malignancy
Description
Inclusion Criteria:
- All diagnosed patients with a primary penile malignancy, including those with squamous carcinoma
Exclusion Criteria:
- No patient meeting the above criteria will be excluded
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational (data collection)
Patients undergo data collection every 6 months for up to 15 years.
|
Ancillary studies
Data collected
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prospectively collect data on the presenting features, management and outcome of penile carcinoma
Time Frame: Up to 15 years
|
Descriptive statistics will be utilized where applicable to address questions relevant to the study aims.
|
Up to 15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Curtis A Pettaway, M.D. Anderson Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 22, 2004
Primary Completion (Actual)
September 17, 2025
Study Completion (Actual)
September 17, 2025
Study Registration Dates
First Submitted
July 30, 2021
First Submitted That Met QC Criteria
July 30, 2021
First Posted (Actual)
August 9, 2021
Study Record Updates
Last Update Posted (Estimated)
September 24, 2025
Last Update Submitted That Met QC Criteria
September 18, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCR04-0148 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-07693 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.